Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Alterity Therapeutics moves neuroprotective drug to Phase 2 trials
    • News

    Alterity Therapeutics moves neuroprotective drug to Phase 2 trials

    Seven to ten years. That’s how long someone diagnosed with multiple system atrophy (MSA) has to live from when symptoms first appear. The progressive disease results in the gradual functional decline of the body’s involuntary functions such as blood pressure, breathing, bladder function and motor control. Often confused with Parkinson’s which is characterised by the

    Read More
    Public
  • Bubs to the rescue as special operation gets underway
    • News

    Bubs to the rescue as special operation gets underway

    Shareholders of Bubs Australia (ASX: BUB) reveled in every small cap investors’ dream over the weekend – a direct shoutout from the President of the United States. And this morning the President issued a follow-up that will renew shareholders’ excitement – it might not quite get the attention of an incendiary ex President Trump tweet,

    Read More
    Public
  • The Cancer Index: Why investing in oncology biotechs is more science than art
    • News

    The Cancer Index: Why investing in oncology biotechs is more science than art

    Despite what it may look like, investing in biotechs is more science than art. The sector holds intrinsically higher risk, but investing in it can be well worth it to those willing to take the plunge. In fact, over the last twenty years biotech firms have outperformed the S&P 500 and both the medtech andRead More
    Public
  • Phase II begins for FirstWave’s cyber defence platform
    • News

    Phase II begins for FirstWave’s cyber defence platform

    Cyber crimes worldwide have been getting worse as the internet gets better, with reports from the national cybersecurity agency in Australia reporting cybercrimes increasing 13% in 2021, with an incident occurring on average every 8 minutes. As new attack methods and vectors, and the use of sophisticated AI evolve, the average business loss from email

    Read More
    Public
  • Forget the details, Mighty Kingdom has just inked a deal with Google
    • News

    Forget the details, Mighty Kingdom has just inked a deal with Google

    Gaming company Mighty Kingdom (ASX: MKL) has partnered with some of the world’s most recognised brands like LEGO, Disney and now Google, with the Company today announcing a new contract. Google will work with Mighty Kingdom for an upcoming technology partnership under a fixed term six month ‘work for hire’ agreement. Any description of the

    Read More
    Public
  • Envirosuite’s machine learning wastewater tech ahead of schedule, accelerates growth
    • News

    Envirosuite’s machine learning wastewater tech ahead of schedule, accelerates growth

    Environmental intelligence company Envirosuite (ASX: EVS) has provided a promising update on its newest product, EVS Water, which has picked up new customers in Australia, Asia , Europe and the US with revenues ahead of originally forecast. The technology is close to achieving its initial goal of $1m in total sales, only one year into

    Read More
    Public
  • «
  • ‹
  • 372
  • 373
  • 374
  • 375
  • 376
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.